Still, given the strong association between PDGFRB and survival in our study, clinical trials including more patients with more specific PDGFRB inhibitors and AI‐based PDGFRB in situ analysis of patient tumor tissue are warranted. The gene discussed is PDGFRB; the disease is neoplasm.